CP.TO 0.88VRT 8.93NVDA -0.07TSM 5.21JPM 2.67ZST.TO 0.01HSAV.TO -0.1HSUV.U.TO 0.01
Summit Therapeutics (SMMT)

NASDAQ:SMMT

Summit Therapeutics (SMMT)

17.55
+0.55 (3.24%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
1 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Summit Therapeutics(SMMT)

Sep 12, 2025
The results of their cancer screening drug were poor

Move on. 

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$18.94

Stock price when the opinion was issued

$17.55

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Summit Therapeutics(SMMT)

Jan 31, 2025

Doesn't make money and is a risky spec.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$21.50

Stock price when the opinion was issued

$17.55

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 1 to 2 of 2 entries
  • «
  • ‹
  • 1
  • ›
  • »

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

KMB -0.33$98.15
XLV -0.3$165.36
META 3.65$648.03
DAL 1.67$79.91
ORCL -2.66$150.28
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 0.88$123.84
VRT 8.93$257.06
NVDA -0.07$218.29
TSM 5.21$433.24
JPM 2.67$356.23

Popular Articles

Latest Sell Signals

ORCL -2.66$150.28
ORCL -2.66$150.28
URI 0.04$989.12
BBD.B.TO -4.9$300.82
BN.TO 0.29$52.93

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Greg Newman

Greg Newman

Scotia Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

Summit Therapeutics (SMMT) Frequently Asked Questions

What is Summit Therapeutics stock symbol?

Summit Therapeutics is a American stock, trading under the symbol SMMT (previously SMMT-Q on Stockchase) on the NASDAQ (SMMT). It is usually referred to as NASDAQ:SMMT or SMMT

Is Summit Therapeutics a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on SMMT (previously SMMT-Q on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Summit Therapeutics.

Is Summit Therapeutics a good investment or a top pick?

Summit Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Summit Therapeutics.

Why is Summit Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Summit Therapeutics.

Is Summit Therapeutics worth watching?

Summit Therapeutics is covered by Stockchase experts and is worth watching.

What is Summit Therapeutics stock price?

On 2026-09-11, Summit Therapeutics (SMMT) stock closed at a price of $17.55.